Establishing a national platform to facilitate patient recruitment and advanced diagnostics for cancer immunotherapies (the NHS Cancer Vaccine Launch Pad): a multicentre prospective cohort feasibility study protocol

Coverage, in order

1. 2d ago
   first BMJ Open UK indie study observational

   Establishing a national platform to facilitate patient recruitment and advanced diagnostics for cancer immunotherapies (the NHS Cancer Vaccine Launch Pad): a multicentre prospective cohort feasibility study protocol

   STRENGTHS AND LIMITATIONS OF THIS STUDY The multicentre prospective design of this study enables evaluation of patient referral and sample-processing pathways using NHS infrastructure across the UK. Standardised referral and tissue-processing pathways support consistent operational delivery across…

2. 2d ago
   medRxiv (all subjects) obscure study randomized trial

   OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study

   Survivin (BIRC5) is broadly overexpressed in human cancers but, as a self-antigen, is subject to immune tolerance that limits spontaneous antitumour immunity. OVM-200 is a recombinant overlapping peptide vaccine spanning full-length survivin, with cathepsin S-cleavable linker sequences inserted…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.